Table of Contents
List of Tables
List of Figures
Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Alzheimer's Disease Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Alzheimer's Disease
Apr 27, 2026: Voyager IV-Delivered CNS Gene Therapies in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease
Apr 22, 2026: IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
Apr 20, 2026: Last Patient Has Completed Alzecure’s Phase Ib Clinical Study With Neurorestore ACD856
Apr 14, 2026: Alzheon to Present Trials with Valiltramiprosate in Alzheimer’s Patients at 2026 American Academy of Neurology Meeting in Chicago, Illinois
Apr 14, 2026: IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
Apr 14, 2026: Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease
Apr 09, 2026: NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit
Apr 08, 2026: NeuroTherapia concludes Phase IIa trial of NTRX-07 for Alzheimer's
Apr 08, 2026: Luye Pharma Announces First Subject Enrolled in the Phase II Clinical Trial in China of the Group’s Innovative Drug LY03020
Apr 07, 2026: Alzheon Advances Industry-Leading Portfolio of Oral Anti-Amyloid Aggregation Inhibitors in Phase 1 of ALZ-507
Apr 07, 2026: IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease
Mar 31, 2026: Annovis Publishes Historical Review of Buntanetap in The Scientist
Mar 26, 2026: Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 “Lithium in Brain” Study; AL001 Achieves Bioequivalence
Mar 23, 2026: NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements in Alzheimer’s Disease at AD/PD 2026
Mar 23, 2026: New Data on Long-Term, Real-World Treatment with Lecanemab Presented at the 2026 AD/PD Congress
Mar 23, 2026: InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program
Mar 21, 2026: Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD 2026
Mar 20, 2026: Galimedix Therapeutics Presents Strong Pharmacokinetic Profile of Next-Generation Oral Alzheimer’s Candidate at AD/PD 2026
Mar 20, 2026: Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026
Mar 19, 2026: AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at the Alzheimer's Conference AD/PD
Mar 19, 2026: ImmunoBrain Presents Clinical Data for First Immune Checkpoint Therapy Approach in Alzheimer's Disease at AD/PD 2026
Mar 19, 2026: INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early AD
Mar 19, 2026: CervoMed Announces New Data at AD/PD 2026 Scientific Conference that Reinforce Neflamapimod’s Effects inDLB in Patients without Alzheimer’s Disease
Mar 19, 2026: AlzeCure presents new preclinical data with NeuroRestore ACD856 at the Alzheimer’s Conference AD/PD
Mar 18, 2026: Qilu Pharmaceutical’s QLH2405 Received Clinical Approval. Targeting AD via Subcutaneous Injection, Phase I Trial Initiated With 68 Participants
Mar 17, 2026: Priavoid Presents Initial Phase 2 Data Suggesting Favorable Safety Profile for Alzheimer’s Candidate PRI-002 at AD/PD 2026
Mar 17, 2026: Acumen Presents Studies on Brain Delivery, Biomarker Research, and Antibodies at Advances in Alzheimer's Treatment at Conference on AD/PD 2026
Mar 16, 2026: Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in with BD in Collaboration with Massachusetts General Hospital
Mar 16, 2026: Amlogenyx Announces Positive Preclinical Data on AM805, a Potent Amyloid-Degrading Protease for the Treatment of Alzheimer’s Disease
Mar 16, 2026: Lundbeck advances Parkinson’s research with new Phase 1b data at AD/PD 2026
Mar 13, 2026: From New Drugs to AI and DTx, Korean Biotechs Take Global Stage at Ad/PD 2026
Mar 12, 2026: BioVie Announces Abstract Accepted for Presentation at AD/PD 2026
Mar 12, 2026: Vanqua Bio to Present at the AD/PD 2026 International Conference
Mar 12, 2026: ImmunoBrain to Present Topline Phase 1b Clinical Data for Immune Checkpoint Treatment in Alzheimer's Disease at AD/PD 2026
Mar 11, 2026: Latest Data on Long-Term, Real-World Treatment with Lecanemab Will Be Presented at the AD/PD 2026 Congress
Mar 11, 2026: Arvinas to Present Phase 1 Data for ARV-102, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases
Mar 10, 2026: NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer’s Disease at AD/PD 2026
Mar 10, 2026: Alzheon to Present Clinical, Imaging, and Fluid Biomarker Results from Trials with Oral Valiltramiprosate/ALZ-801 at 2026 AD/PD Conference in Denmark
Mar 05, 2026: Galimedix Therapeutics to Present Promising Pre-clinical Data with Next Generation Oral Amyloid Beta Aggregation Modulator at AD/PD 2026 Conference
Mar 05, 2026: Priavoid to Present Initial Phase 2 Safety Data for Alzheimer‘S and Preclinical PoC for Parkinson‘S Programs at AD/PD 2026
Mar 05, 2026: Alzinova to Participate in Several International Industry and Investor Events During Spring and Summer 2026
Mar 04, 2026: Transposon Therapeutics’ TPN-101 to Be Studied for Extending Healthy Aging Under ARPA-H Award for up to $22M
Mar 03, 2026: Annovis Announces Two Presentations at the AD/PD 2026 International Conference
Mar 03, 2026: Acumen to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
Feb 25, 2026: Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study
Feb 24, 2026: AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
Feb 23, 2026: INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
Feb 23, 2026: IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
Feb 17, 2026: IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances
Feb 16, 2026: Alzinova Engages Renowned International Alzheimer’s Expert as Global Principal Investigator Ahead of Planned Phase 2 Study
Feb 12, 2026: Inmune Bio Announces FDA Alignment on Integrated Phase 2B/3 Registration Pathway for XPRO1595 in Early Alzheimer’s Disease
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Source
